In neuroblastoma, the impairment of p53 signalling is seldom caused by inactivating mutations of the p53 gene [15, 16] but is more commonly due to upstream aberrations such as amplification of the p53 negative regulator MDM2 and inactivation of the MDM2 inhibitor p14(ARF) [17]. Here, MDM2 is linked to neuroblastoma.